Form 4: Zenas BioPharma Director Acquires $1.2M in Common Stock

Zenas BioPharma Director Jason Raleigh Nunn indirectly acquired 63,158 shares of common stock from the issuer at $19 per share, totaling approximately $1.2 million.

Summary

• Jason Raleigh Nunn, a Director of Zenas BioPharma, Inc. (ZBIO), acquired 63,158 shares of common stock.
• The transaction occurred on October 9, 2025, at a price of $19 per share, totaling $1,199,902.
• The acquisition was made from the Issuer pursuant to a Securities Purchase Agreement dated October 7, 2025.
• Following this transaction, Mr. Nunn indirectly beneficially owns 1,173,395 shares through SR One Capital Opportunities Fund I, LP.
• Additionally, Mr. Nunn indirectly beneficially owns 1,946,564 shares through SR One Capital Fund II Aggregator, LP.
• Mr. Nunn disclaims beneficial ownership of these securities for Section 16 purposes, except to the extent of his pecuniary interest therein.

Sentiment

Score: 8

Explanation: The acquisition of a significant number of shares by a director, especially directly from the issuer, generally indicates strong insider confidence in the company's valuation and future prospects, leading to a positive sentiment.

Positives

• A director's acquisition of a significant number of shares (over $1.1 million) can signal strong confidence in the company's future prospects and valuation.
• The acquisition was made directly from the Issuer, indicating a direct investment into the company.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's future performance, but the insider purchase may be interpreted as a positive signal for future prospects.

Industry Context

This insider purchase by a director of Zenas BioPharma, a biotechnology company, suggests confidence in the company's pipeline or strategic direction, which is a common signal observed in the biotech industry where insider sentiment can be a key indicator.

Related Party Transactions

• The reporting person, Jason Raleigh Nunn, is a Director of Zenas BioPharma, Inc. and acquired shares directly from the Issuer.
• Mr. Nunn is a partner of SR One Capital Management, LP, an entity affiliated with the funds (SR One Capital Opportunities Fund I, LP and SR One Capital Fund II Aggregator, LP) that indirectly hold the reported securities, establishing a related party relationship.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The company benefits from the capital raised through the direct issuance of shares to the director's affiliated entities.

Key Dates

Recommendation

The significant acquisition of shares by a director, particularly directly from the issuer, is a strong signal of insider confidence in the company's future performance and valuation. This type of transaction often precedes positive developments or reflects a belief that the stock is undervalued, making it an attractive buying opportunity for seasoned investors.

Keywords

Zenas BioPharma, ZBIO, Insider Trading, Form 4, Stock Acquisition, Director, Beneficial Ownership, Equity Investment, SR One Capital